Market access Switzerland: the process for manufacturers

The chain from authorisation to a reimbursed product

The path has five links: an authorisation holder domiciled in Switzerland, the Swissmedic authorisation, the admission request to the FOPH, the price negotiation, and distribution through a licensed wholesaler. Every link has its own deadlines, and any one of them can block the launch on its own.

Foreign manufacturers need an authorisation holder domiciled in Switzerland and a responsible person for technical matters. That role can be built in house or held on a fiduciary basis by a Swiss partner and transferred to you later.

• An authorisation holder domiciled in Switzerland with a responsible person for technical matters.
• Swissmedic authorisation under the Therapeutic Products Act, with professional information in German and French.
• The SL request to the FOPH within 60 days of authorisation.
• Price negotiation and ruling, then publication on the first of a month.
• Distribution through a wholesaler with an operating licence and GDP compliance.

Pricing strategy before filing

The Swiss price comes out of the foreign price comparison against nine reference countries and the therapeutic cross comparison. Both values are already fixed by the time you file, because they rest on your prices in Germany, France, Austria and the other reference markets.

From that follows the single most important rule of Swiss market access: the launch sequence is part of pricing strategy. Launching first in a low-price country permanently lowers the Swiss reference, and every three-yearly review pulls it down again.

1. Model the reference country prices, including the customary discounts and mandatory rebates.
2. Set the launch sequence: high-price countries and Switzerland before the low-price markets.
3. Identify the comparator products in the IT group and calculate daily treatment costs.
4. Assess an innovation premium and support it with clinical evidence.
5. Sign off the price corridor internally before the filing date is set.

The SL dossier and the commission

The request follows the FOPH handbook on the Specialities List. It contains the admission form, the foreign price comparison with a source per country, the therapeutic cross comparison, a three-year turnover forecast, a proposed limitation text and, where needed, a price model.

The Federal Drug Commission acts in an advisory role. It meets on a fixed cadence and assesses efficacy, appropriateness and cost effectiveness under Art. 32 of the Health Insurance Act. A missed meeting date costs weeks immediately, which is why dossier completeness beats speed.

• A formally incomplete request is returned, not corrected.
• The limitation proposal belongs in the dossier: leaving it to the FOPH usually yields the narrower version.
• Price models with rebates, pay-back or volume caps are permitted and agreed confidentially.

The first three years and the review

Publication does not start a quiet period, it starts the review cycle. Under Art. 65d of the Health Insurance Ordinance the FOPH reassesses every preparation every three years and recalculates both the foreign price comparison and the therapeutic cross comparison. Indication extensions also trigger a price review.

An indication extension cuts both ways economically: it opens volume but triggers a fresh cross comparison and can lower the price. Both effects belong in the same calculation, before the request is filed.

Hospital and pharmacy are two markets

The SL price is a maximum price for reimbursement by Swiss mandatory health insurance. It does not bind hospital procurement: hospitals and purchasing groups negotiate their own terms through tenders, often far below the published ex-factory price.

• Outpatient: the SL price, the distribution share, the co-payment and the differentiated co-payment drive demand.
• Inpatient: tenders, rebates and the case-based payment system drive the price.
• Mixed forms: outpatient administration in a hospital is billed through the SL and follows the maximum price.

Serving both channels with a single pricing logic loses either the hospital or the published price. Channel separation therefore belongs in the pricing strategy, not only in the distribution plan.

Distribution, wholesale and pharmacovigilance

Before the first sale, three licences and one organisation must be in place: the operating licence for wholesale or import, GDP compliant logistics, the responsible person for technical matters, and a working pharmacovigilance system with the reporting routes of Art. 59 of the Therapeutic Products Act.

• A Swissmedic operating licence for import, wholesale and export.
• GDP compliant storage, temperature monitoring and batch traceability.
• A responsible person for technical matters with sufficient availability and authority to instruct.
• Pharmacovigilance: reporting deadlines, periodic reports, a contact point in Switzerland.
• A recall plan able to trigger a batch recall within hours.

These are not a side note to market access, they are its precondition. A published SL entry with no wholesaler able to deliver hands market share to the competitor who can ship on the first day of the month.